全文获取类型
收费全文 | 898720篇 |
免费 | 63546篇 |
国内免费 | 2327篇 |
专业分类
耳鼻咽喉 | 12476篇 |
儿科学 | 28677篇 |
妇产科学 | 26182篇 |
基础医学 | 126605篇 |
口腔科学 | 24685篇 |
临床医学 | 74777篇 |
内科学 | 183172篇 |
皮肤病学 | 19013篇 |
神经病学 | 71389篇 |
特种医学 | 36457篇 |
外国民族医学 | 337篇 |
外科学 | 142142篇 |
综合类 | 19029篇 |
一般理论 | 247篇 |
预防医学 | 64599篇 |
眼科学 | 20084篇 |
药学 | 63814篇 |
中国医学 | 1799篇 |
肿瘤学 | 49109篇 |
出版年
2018年 | 9056篇 |
2017年 | 7166篇 |
2016年 | 7681篇 |
2015年 | 8731篇 |
2014年 | 12376篇 |
2013年 | 19214篇 |
2012年 | 25670篇 |
2011年 | 27274篇 |
2010年 | 16581篇 |
2009年 | 15786篇 |
2008年 | 26138篇 |
2007年 | 27744篇 |
2006年 | 27925篇 |
2005年 | 27457篇 |
2004年 | 26302篇 |
2003年 | 25467篇 |
2002年 | 25058篇 |
2001年 | 41366篇 |
2000年 | 42560篇 |
1999年 | 36271篇 |
1998年 | 9969篇 |
1997年 | 9152篇 |
1996年 | 9083篇 |
1995年 | 8449篇 |
1994年 | 8083篇 |
1993年 | 7585篇 |
1992年 | 28205篇 |
1991年 | 26984篇 |
1990年 | 26411篇 |
1989年 | 25347篇 |
1988年 | 23555篇 |
1987年 | 23172篇 |
1986年 | 22252篇 |
1985年 | 21155篇 |
1984年 | 15809篇 |
1983年 | 13483篇 |
1982年 | 8088篇 |
1979年 | 14590篇 |
1978年 | 10211篇 |
1977年 | 8628篇 |
1976年 | 8147篇 |
1975年 | 8962篇 |
1974年 | 10700篇 |
1973年 | 10182篇 |
1972年 | 9661篇 |
1971年 | 8917篇 |
1970年 | 8585篇 |
1969年 | 8026篇 |
1968年 | 7686篇 |
1967年 | 7086篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
T.F.A. Lees L. Bogdashich D. Godden 《The British journal of oral & maxillofacial surgery》2021,59(1):e9-e12
Fibroepithelial polyps (FEPs) are common, benign intraoral lesions that tend to develop slowly at predictable sites, often in response to local irritation or trauma. Historical precedent often results in referral to oral and maxillofacial surgery (OMFS) departments for biopsy, often irrespective of symptoms, and histological assessment. OMFS and pathology services are struggling to cope with an increasing workload that will potentially lead to widespread delays to diagnosis and treatment. Over the past 20 years, clinical pathways and guidance have been developed to ensure that healthcare interventions, such as the removal of third molars, tonsils, skin tags, and benign moles, are evidence-based, have a net patient benefit, and ensure the best use of finite NHS resources. However, no such guidance exists for intraoral lesions and we regard this as an oversight. We analysed the removal of 682 FEPs over a seven-year period and report sensitivities of 92.4% for a “confirmed clinical suspicion of an FEP” and 99.7% for a “confirmed clinical suspicion of a benign diagnosis”. The incidence of non-benign disease was 0.3%. Primary care dentists should be able to diagnose and monitor FEPs and refer only if symptoms are serious or in high-risk patients or sites. Adopting this practice across the UK could free up to 1825 four-hour OMFS clinics, 405 hours of consultant histopathologists’ time, and recurring savings to the NHS estimated to be in the region of £620 000/annum. We believe that the removal of FEPs should be reclassified as an “intervention not normally funded”, and the time and resources put to better use treating patients with lesions of questionable pathology. 相似文献
82.
Yang Chih-Hsiang Wang Shirlene Wang Wei-Lin Belcher Britni R. Dunton Genevieve F. 《Journal of behavioral medicine》2022,45(5):702-715
Journal of Behavioral Medicine - Understanding associations between mothers’ and children’s physical activity and sedentary behavior on more fine-grained timescales can provide insights... 相似文献
83.
84.
In both adults and children with diabetes, technologies such as continuous subcutaneous insulin infusion using insulin pumps and continuous glucose monitoring can help improve diabetes control, reduce hypoglycaemia and improve quality of life. Access to these technologies in the UK is very variable. Some technologies are recommended by the National Institute for Health and Care Excellence, while others have not been appraised, and new technologies are emerging all the time. Additionally, different guidelines for adults and children further complicate access to diabetes technology in the transition from paediatric to adult care. Against this background, Diabetes UK and NHS England have brought together a multidisciplinary group of experts, including clinicians and people with diabetes, to develop this consensus guideline, combining the different technologies into a common pathway to aid clinical and policy decision‐making. We created a pathway that supports the incremental addition of technology as monotherapy and then dual therapy in the same way that we incrementally add in therapeutic agents to support people with Type 2 diabetes to achieve their personalized glycaemic targets. The pathway emphasizes the importance of structured education, specialist support and appropriate access to psychological therapies, as essential pillars for optimized use of diabetes‐related technology, and recommends the re‐evaluation of its use when the individual is unable either to use the technology appropriately or to achieve the intended outcomes. This pathway is endorsed by UK‐wide clinical and patient associations and we recommend that providers and commissioners use it to ensure the right individual with diabetes has access to the right technology in a timely way to help achieve better outcomes. 相似文献
85.
Familial risk and heritability of intellectual disability: a population-based cohort study in Sweden
86.
87.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献88.
89.
90.